[
{
	"page":"ENAS5407_1.0.0.0",
	"text":"1.0.0.0 Authors and legal information GUIDELINES COMMITTEE Chair: George Pentheroudakis; Co-Chair: Cristiana Sessa; Steering Committee Members: Dirk Arnold, Christian Buske, Fatima Cardoso, Paolo Casali, Andrés Cervantes, Elisabeth De Vries, Alan Horwich, Solange Peters, Rolf Stahel; Subject Editors: Jean-Yves Blay, Nicoletta Colombo, Karin Jordan, Ulrich Keilholz, Marco Ladetto, Lisa Licitra, Matthias Preusser, Carla Ripamonti, Elzbieta Senkus-Konefka; Deputy Subject Editors: Alfredo Berruti, Silke Gillessen, Mats Jerkeman, Jean-Pascal Machiels, Erika Martinelli, Ulrich Mey, Olivier Michielin, Martin Reck; Staff: Keith McGregor, Claire Bramley, Jennifer Lamarre, Sarah Escuin, Jean-Yves Douillard, Svetlana Jezdic. ESMO CLINICAL PRACTICE GUIDELINES Early colon cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-‍‍up Labianca R, Nordlinger B, Beretta GD, Mosconi S, Mandalà M, Cervantes A and Arnold D, on behalf of the ESMO Guidelines Working Group Ann Oncol 2013;24(Suppl 6):vi64–72 http:/​/​‍annonc.oxfordjournals.org/​‍content/‍​24/​suppl_6/​‍vi64.full.pdf+html Rectal cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-‍‍up Glynne-Jones R, Wyrwicz L, Tiret E, Brown G, Rödel C, Cervantes A and Arnold D, on behalf of the ESMO Guidelines Committee Ann Oncol 2017;28(Suppl 4):iv22–40 https://academic.oup.com/annonc/article-pdf/28/suppl_4/iv22/3958158/mdx224.pdf Familial risk - colorectal cancer: ESMO Clinical Practice Guidelines Balmaña J, Balaguer F, Cervantes A and Arnold D, on behalf of the ESMO Guidelines Working Group Ann Oncol 2013;24(Suppl 6):vi73–80 http:/​/​annonc.oxfordjournals.org/​content/‍​‍‍24/​‍suppl_6/​vi73.full.pdf+html Anal cancer: ESMO-‍ESSO-‍ESTRO Clinical Practice Guidelines for diagnosis, treatment and follow-‍‍up Glynne-‍‍Jones R, Nilsson PJ, Aschele C, Goh V, Peiffert D, Cervantes A and Arnold D Ann Oncol 2014; 25(Suppl 3):iii10-20. http:/​/​annonc.oxfordjournals.org/​content/‍​‍‍25/​‍suppl_3/​iii10.full.pdf+html   Metastatic colorectal cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-‍‍up Van Cutsem E, Cervantes A, Nordlinger B and Arnold D, on behalf of the ESMO Guidelines Working Group Ann Oncol 2014; 25 (Suppl 3):iii1-9 http:/​/​annonc.oxfordjournals.org/​content/‍​‍‍25/​‍suppl_3/​iii1.full.pdf+html ESMO CONSENSUS STATEMENTS ESMO Consensus Guidelines for Management of Patients with Metastatic Colorectal Cancer Van Cutsem E, Cervantes A, Adam R, Sobrero A, Van Krieken JH, Aderka D, Aranda Aguilar E, Bardelli A, Benson A, Bodoky G, Ciardiello F, D’Hoore A, Diaz-‍Rubio E, Douillard JY, Ducreux M, Falcone A, Grothey A, Gruenberger T, Haustermans K, Heinemann V, Hoff P, Köhne CH, Labianca R, Laurent-‍‍Puig P, Ma B, Maughan T, Muro K, Normanno N, Österlund P, Oyen WJG, Papamichael D, Pentheroudakis G, Pfeiffer P, Price TJ, Punt C, Ricke J, Roth A, Salazar R, Scheithauer W, Schmoll HJ, Tabernero J, Taïeb J, Tejpar S, Wasan H, Yoshino T, Zaanan A and Arnold D Ann Oncol 2016; 27: 1386-422. http:/​/​‍annonc.oxfordjournals.org/​‍content/‍​‍‍‍27/​8/​1386.full.pdf+html ESMO POCKET GUIDELINES PROVIDE YOU WITH A CONCISE SUMMARY OF THE FUNDAMENTAL RECOMMENDATIONS MADE IN THE PARENT GUIDELINES IN AN EASILY ACCESSIBLE FORMAT. This quick reference booklet provides you with the most important content of the full ESMO Clinical Practice Guidelines (CPG) and consensus statements on the management of lower gastrointestinal (GI) tumours (early colon cancer, rectal cancer, familial colorectal cancer [CRC] risk, metastatic CRC and anal cancer). Key content includes diagnostic criteria, staging of disease, treatment plans and follow-‍‍up. The ESMO CPG and consensus statements on lower GI tumours are intended to provide you with a set of recommendations for the best standards of care for lower GI tumours, using evidence-‍‍based medicine. Implementation of ESMO CPG and consensus statements facilitates knowledge uptake and helps you to deliver an appropriate quality of focused care to your patients. The approval and licensed indication of drugs mentioned in this pocket guideline may vary in different countries. Please consult your local prescribing information. This booklet can be used as a quick reference guide to access key content on evidence-‍‍based management of lower GI tumours. Please visit http:/​/​www.esmo.org or http:/​‍/​‍oncologypro.esmo.org to view the full guidelines and consensus statements."
},
{
	"page":"ENAS5407_2.1.0.0",
	"text":"2.0.0.0 Diagnosis and pathology 2.1.0.0 Overview Diagnosis is based on a digital rectal examination (DRE) and endoscopy, with biopsy for histopathological confirmation, as shown in this figure Rectal cancers have distal extension to ≤ 15 cm from the anal margin, using rigid sigmoidoscopy, and are categorised as low (≤ 5 cm), middle (from > 5 to 10 cm) or high (from > 10 up to 15 cm) There is a wide overlap of molecular genomic profiles of left-‍sided /​ sigmoid with rectal cancer; so rectal cancer cannot be seen as a molecularly defined different entity"
},
{
	"page":"ENAS5407_3.1.0.0",
	"text":"3.0.0.0 STAGING AND RISK ASSESSMENT 3.1.0.0 Overview A specialised trained and dedicated multidisciplinary team (MDT) of radiologists, surgeons, radiation oncologists, medical oncologists and pathologists should manage patients A history and physical examination, including DRE, full blood count, liver and renal function tests, serum carcinoembryonic antigen (CEA) and computed tomography (CT) scan of thorax and abdomen, should be carried out to define functional status and presence of metastases, as shown in this figure Positron emission tomography-‍computed tomography (PET-‍CT), as shown in this table, may provide information on disease outside the pelvis"
},
{
	"page":"ENAS5407_3.3.0.0",
	"text":"3.3.0.0 DIAGNOSTIC WORK-‍UP IN PRIMARY RECTAL CANCER PARAMETER METHOD OF CHOICE Location (distance from anal verge) DRE/​‍Palpation Rigid sigmoidoscopy (flexible endoscopy)* Morphological verification Biopsy cT stage Early   Intermediate/‍​‍advanced   ERUS MRI MRI (ERUS)* Sphincter infiltration MRI (ERUS, palpation, EUA)* cN stage MRI (CT, ERUS)* M stage CT, MRI (or US)* of the liver/‍​abdomen CT of the thorax PET-‍CT if extensive EMVI for other sites Evaluation for all patients MDT discussion *Methods within brackets are less optimal cN, clinical node stage; cT, clinical tumour stage; CT, computed tomography; DRE, digital rectal examination; EMVI, extramural vascular invasion; ERUS, endorectal ultrasound; EUA, examination under anaesthetic; MDT, multidisciplinary team; MRI, magnetic resonance imaging; PET-‍CT, positron emission tomography-‍computed tomography; US, ultrasound Older patients have higher early postoperative mortality and worse toxicity from radiotherapy (RT) and chemotherapy (ChT), and pretreatment formal geriatric assessment, or frailty screening, is recommended in patients over 70 years Rigid rectoscopy and preoperative colonoscopy to the caecal pole are required, or, in the case of obstruction, virtual colonoscopy In the absence of preoperative (virtual) colonoscopy, completion colonoscopy is recommended within 6 months of surgery Endorectal ultrasound (ERUS) may define treatment for the earliest tumours and determination of mucosal or submucosal (sm) restriction can identify tumours appropriate for transanal endoscopic microsurgery (TEM) ERUS offers less value in locally advanced rectal cancer (LARC) Pelvic magnetic resonance imaging (MRI) is the most accurate test for locoregional clinical staging and should be carried out to select patients for preoperative management and to define the extent of surgery The Union for International Cancer Control (UICC) tumour node metastasis (TNM) staging classification used should be documented in the report; the 8th edition is shown in this table"
},
{
	"page":"ENAS5407_3.4.0.0",
	"text":"3.4.0.0 The UICC TNM staging TNM CLINICAL CLASSIFICATION T – Primary Tumour TX Primary tumour cannot be assessed T0 No evidence of primary tumour Tis Carcinoma in situ: Invasion of lamina propria* T1 Tumour invades submucosa T2 Tumour invades muscularis propria T3 Tumour invades subserosa or into non-‍peritonealised pericolic or perirectal tissues T4 Tumour directly invades other organs or structures†,‡,§ and/​‍or perforates visceral peritoneum T4a Tumour perforates visceral peritoneum T4b Tumour directly invades other organs or structures N – Regional Lymph Nodes NX Regional lymph nodes cannot be assessed N0 No regional lymph node metastasis N1 Metastasis in 1 to 3 regional lymph nodes N1a Metastasis in 1 regional lymph node N1b Metastasis in 2–3 regional lymph nodes N1c Tumour deposit(s), i.e. satellites,|| in the subserosa, or in non-‍peritonealised pericolic or perirectal soft tissue without regional lymph node metastasis N2 Metastasis in 4 or more regional lymph nodes N2a Metastasis in 4–6 regional lymph nodes N2b Metastasis in 7 or more regional lymph nodes M-‍Distant Metasis M0 No distant metastasis M1a Distant metastasis M1a Metastasis confined to one organ (liver, lung, ovary, non-‍regional lymph node(s)) without peritoneal metastases M1b Metastasis in more than one organ M1c Metastasis to the peritoneum with or without organ involvement *Tis includes cancer cells confined within the mucosal lamina propria (intramucosal) with no extension through the muscularis mucosae into the submucosa †Invades through to visceral peritoneum to involve the surface ‡Direct invasion in T4b includes invasion of other organs or segments of the colorectum by way of the serosa, as confirmed on microscopic examination, or for tumours in a retroperitoneal or subperitoneal location, direct invasion of other organs or structures by virtue of extension beyond the muscularis propria §Tumour that is adherent to other organs or structures, macroscopically, is classified cT4b. However, if no tumour is present in the adhesion, microscopically, the classification should be pT1–3, depending on the anatomical depth of wall invasion ║Tumour deposits (satellites) are discrete macroscopic or microscopic nodules of cancer in the pericolorectal adipose tissue’s lymph drainage area of a primary carcinoma that are discontinuous from the primary and without histological evidence of residual lymph node or identifiable vascular or neural structures. If a vessel wall is identifiable on H&E, elastic or other stains, it should be classified as venous invasion (V1/2) or lymphatic invasion (L1). Similarly, if neural structures are identifiable, the lesion should be classified as perineural invasion (Pn1). The presence of tumour deposits does not change the primary tumour T category, but changes the node status (N) to pN1c if all regional lymph nodes are negative on pathological examination H&E, hematoxilin and eosin; TNM, tumour node metastasis; UICC, Union for International Cancer Control Brierley JD et al. TNM Classification of Malignant Tumours, 8th edition: John Wiley & Sons, Inc., Oxford, 2016. Reprinted with permission from John Wiley & Sons, Inc. Further subclassification of cT3 is recommended, as shown in this table"
},
{
	"page":"ENAS5407_3.5.0.0",
	"text":"3.5.0.0 SUBCLASSIFICATION OF T3 RECTAL CANCER T3 STAGE DEPTH OF INVASION BEYOND THE MUSCULARIS PROPRIA, MM T3a* < 1 T3b 1-5 T3c 6-15 T3d > 15 *This subclassification, based on pretreatment decision MRI evaluation, is clinically valuable and can be used also in the histopathological classification, although it is not validated nor incorporated in any of the TNM versions MRI, magnetic resonance imaging; TNM, tumour node metastasis Edge SB et al. AJCC Cancer Staging Handbook, 7th edition: Springer, New York, 2010. Reprinted with permission."
},
{
	"page":"ENAS5407_3.6.1.0",
	"text":"3.6.0.0 Stage grouping of colon and rectal cancer 3.6.1.0 Overview Stage grouping is shown in this table Clinical nodal staging is unreliable, even using ERUS, CT and MRI combined Therefore, N staging is not of high importance to clinical decision making The relationship between tumour and mesorectal fascia (MRF) is more crucial than lymph node status Irregular border and heterogeneous signal provide relevant additional information PET-‍CT should not be used routinely for initial staging, but can be used in conjunction with liver MRI and contrast-‍enhanced CT of the thorax, abdomen and pelvis to assess features associated with a high risk of metastases It may also assist with RT target delineation Bone scan and brain imaging should only be carried out if warranted by symptoms"
},
{
	"page":"ENAS5407_3.6.2.0",
	"text":"3.6.2.0 TNM pathological classification TNM PATHOLOGICAL CLASSIFICATION The pT and pN categories correspond to the T and N categories pN0 Histological examination of a regional lymphadenectomy specimen will ordinarily include 12 or more lymph nodes. If the lymph nodes are negative, but the number ordinarily examined is not met, classify as pN0 Stage Stage 0 Tis N0 M0 Stage I T1, T2 N0 M0 Stage II T3, T4 N0 M0 Stage IIA T3 N0 M0 Stage IIB T4a N0 M0 Stage IIC T4b N0 M0 Stage III Any T N1, N2 M0 Stage IIIA T1, T2 N1 M0 T1 N2a M0 Stage IIIB T1, T2 N2b M0 T2, T3 N2a M0 T3, T4a N1 M0 Stage IIIC T3, T4a N2b M0 T4a N2a M0 T4b N1,N2 M0 Stage IV Any T Any N M1 Stage IVA Any T Any N M1a Stage IVB Any T Any N M1b Stage IVC Any T Any N M1c TNM, tumour node metastasis Brierley JD et al. TNM Classification of Malignant Tumours, 8th edition: John Wiley & Sons, Inc., Oxford, 2016. Reprinted with permission from John Wiley & Sons, Inc."
},
{
	"page":"ENAS5407_3.6.3.0",
	"text":"3.6.3.0 Histopathology T1 tumours can be classified according to Haggitt&#39;s sub-‍classification if the cancer is pedunculated; the grade, lymphovascular invasion (LVI) and presence of budding predict the risk of lymph node metastases, enable a risk/​‍benefit assessment of the requirement for further surgery and define the method of excision T1 tumours can be classified according to Kudo/​‍Kikuchi (sm)-‍system if in a sessile adenoma, when the level of infiltration into the sm and the width of invasion should be assessed En bloc resection is recommended for accurate assessment of invasion in the resection margin and the deepest area Radical surgery and removal of lymph nodes is recommended by Japanese guidelines for high-‍risk pathological features, i.e. poorly differentiated with evidence of vascular or lymphatic invasion and an invasion depth of > 1000 μm For mesorectal resections, histopathological examination should include a photographic record of the surgical specimen and assessment of total mesorectal excision (TME) quality Classification covers three grades, based on the completeness of the mesorectal removal and/​‍or the plane of surgical excision, and impacts on both local recurrence and survival TME quality, along with the involved circumferential resection margin (CRM) (i.e.< 1 mm), represents a surrogate parameter for good oncological outcomes, as shown in this table More advanced T-‍stage, tumour distance from the anal verge less than 8 cm, more advanced age and low surgical case volume are independently associated with moderate or poor TME quality At least 12 regional lymph nodes should be examined and margins documented in millimetres Extranodal extension (ENE) of nodal metastases, extramural vascular invasion (EMVI), perineural invasion (PNI) and tumour budding should be evaluated"
},
{
	"page":"ENAS5407_3.6.4.0",
	"text":"3.6.4.0 GRADING OF THE MESORECTUM GRADING OF QUALITY AND COMPLETENESS OF THE MESORECTUM IN A TOTAL MESORECTAL EXCISION SPECIMEN ACCORDING TO THE PLANE OF SURGICAL EXCISION Mesorectal plane (good plane of surgery achieved) Intact mesorectum with only minor irregularities of a smooth mesorectal surface; no defect deeper than 5 mm; no coning; and smooth circumferential resection margin on slicing Intra-‍mesorectal plane (moderate plane of surgery achieved) Moderate bulk to mesorectum, with irregularities of the mesorectal surface; moderate distal coning; muscularis propria not visible with the exception of levator insertion; and moderate irregularities of circumferential resection margin Muscularis propria plane (poor plane of surgery achieved) Little bulk to mesorectum with defects down onto muscularis propria; very irregular circumferential resection margin; or both The specimen is examined as a whole (fresh) and as cross-‍sectional slices (fixed) to make an adequate interpretation A TME specimen ideally should have a smooth surface, without incisions, defects or cracks, as an indication of successful surgical excision of all mesorectal tissue. ‘Coning’ represents the tendency for the surgeon to cut inwards towards the central tube of the rectum during distal dissection, rather than staying outside the visceral mesorectal fascia. The specimen then shows a tapered, conical appearance representing suboptimal surgical quality TME, total mesorectal excision Quirke P et al. Lancet 2009;373:821–8. Reprinted with permission"
},
{
	"page":"ENAS5407_4.2.0.0",
	"text":"4.2.0.0 Tx of primary rectal CA w/out distant met. RECOMMENDED CHOICE OF TREATMENT OPTIONS WITHIN TNM RISK CATEGORY OF PRIMARY RECTAL CANCER WITHOUT DISTANT METASTASES TN SUBSTAGE POSSIBLE THERAPEUTIC OPTIONS FURTHER CONSIDERATIONS Risk Group: Very early cT1sm1 N0 (on ERUS and MRI) Local excision (TEM) If pT1 and no adverse features, adverse features on pathology,TEM is sufficient If adverse histopathology (sm ≥2, G3, V1, L1), requires radical resection (TME) as standard Alternatively, in the case of adverse features on pathology, TEM plus salvage (or adjuvant) CRT in perioperative high-‍risk (but unproven benefit – with high risk of local recurrence for pT2) Risk Group: Early (Good) cT1–cT2; cT3a/b if middle or high, N0 (or also cN1 if high), MRF clear, no EMVI Surgery (TME) alone is standard If unexpected poor prognostic signs on histopathology (CRM+, extranodal/‍N2), consider postoperative CRT/‍ChT* For fragile, high-‍risk patients or those rejecting radical surgery (CRT with evaluation, local excision or if achieving cCR, watch-‍and-‍wait, organ preservation) Risk Group: Intermediate cT3a/b very low, levators clear, MRF clear or cT3a/b in mid- or high rectum, cN1–2 (not extranodal), no EMVI Surgery (TME) alone is a standard only if good-‍quality mesorectal resection assured (and local recurrence ≤ 5% or, if not, preoperative SCPRT (5 × 5 Gy) or CRT followed by TME If CRT is given and cCR achieved, watch-‍and-‍wait in high-‍risk patients for surgery may be considered Risk Group: Bad cT3c, d or very low localisation levators threatened, MRF clear cT3c/d mid-‍rectum, cN1–N2 (extranodal), EMVI+, limited cT4aN0 Preoperative SCPRT (5 × 5 Gy) or CRT followed by TME, depending on need for regression If CRT and cCR achieved, watch-‍and-‍wait in high-‍risk patients may be considered Risk Group: Advanced (Ugly) cT3 with any MRF involved, any cT4a/b, lateral node+ Preoperative CRT followed by surgery (TME and more extended surgery if needed due to tumour overgrowth), or preoperative SCPRT (5 × 5 Gy) plus FOLFOX and delay to surgery Alternatively, 5 × 5 Gy alone with a delay to surgery in fragile/​elderly or in patients with severe comorbidity who cannot tolerate CRT *See table Other factors besides T and N stages are relevant, such as EMVI, MRF involvement, distance from the anus and sphincters, size of mesorectum and patient characteristics Patient preferences are also important cCR, clinical complete response; ChT, chemotherapy; CRT, chemoradiotherapy; EMVI, extramural vascular invasion; ERUS, endorectal ultrasound; FOLFOX, leucovorin/‍​‍fluorouracil/‍​‍oxaliplatin; G, grade; L, lymphatic invasion; MRF, mesorectal fascia; MRI, magnetic resonance imaging; SCPRT, short-‍course preoperative radiotherapy; sm, submucosa; TEM, transanal endoscopic microsurgery; TME, total mesorectal excision; TNM, tumour node metastasis; V, vascular invasion"
},
{
	"page":"ENAS5407_4.3.1.0",
	"text":"4.3.0.0 Risk-‍adapted treatment 4.3.1.0 Very early cT1N0, with low grade (G1/​G2) Very early cT1N0, with low grade (G1/G2) Local excisional procedures, such as TEM, are appropriate as single modalities for early cancers (cT1N0 without adverse features like grade 3, vascular invasion [V]1, lymphatic invasion [L]1) TEM for more advanced T-‍stage may be appropriate for patients at high surgical risk TEM permits more accurate local excision of rectal tumours than local excision and provides similar oncologic results in pT1sm1 (clinical cN0) tumours compared with TME, without compromising anorectal function Where there is unfavourable pTNM assessment following local excision, TME should remain the standard salvage option Local RT (brachytherapy or contact therapy – Papillon technique) may also be used as an alternative to local surgery, alone or combined with chemoradiotherapy (CRT)"
},
{
	"page":"ENAS5407_4.3.2.0",
	"text":"4.3.2.0 Rectal CA not suitable for local excision Early rectal cancer not suitable for local excision (cT1–cT2; cT3a/b if middle or high, N0 [or also cN1 if high], MRF clear, no EMVI) More advanced tumours, up to and including cT2c/​T3a/​b, should be treated by radical TME and the standard of care is excision of all mesorectal fat, including all lymph nodes, although a partial mesorectal excision, with a distal mesorectal margin of at least 5 cm, can be considered in upper rectal cancer Rarely, local excision using TEM can be an option in patients with a cT1 tumour or in elderly or fragile patients The choice of laparoscopic or open surgery should be based on the surgeon’s experience, the tumour stage and location and patient factors, such as obesity and previous open abdominal surgery Transanal total mesorectal excision (TaTME) may facilitate pelvic and distal mesorectal dissection in low rectal tumours, but standardisation and assessment of the technique are required MRI is recommended to select patients suitable for abdominoperineal excision and if the tumour extends into the levators, a cylindrical specimen should be achieved, avoiding a ‘waist’ effect and minimising the risk of a positive CRM and/​ or an R1/2 resection Lateral node dissection (LND) is undertaken in Japan if the tumour is sited below the peritoneal reflection, but is rarely practised in Europe, unless image-‍identified enlarged lateral nodes persist following CRT For cT2 tumours < 4 cm, while local excision after preoperative RT/‍CRT is an alternative to abdominal surgery, functional compromise has not been confirmed, and the strategy is not routinely recommended outside clinical trials, except for elderly, fragile patients at high surgical risk Early, favourable cases not suitable for local excision (i.e. cT1–2 but with adverse pathological features and some cT3a/b without MRI-‍identified involvement of MRF) when located above the levators, may be appropriate for TME alone because of the low local failure risk For complete responders, in patients with cT2–3a tumours, a watch-‍and-‍wait approach or local excision after neoadjuvant CRT is feasible, but should be implemented only in prospective observation protocols"
},
{
	"page":"ENAS5407_4.3.3.0",
	"text":"4.3.3.0 Intermediate/‍​more locally advan. rectal CA Intermediate/more locally advanced rectal cancers (cT3a/b [very low, levators clear, MRF clear] or cT3a/b in mid- or high rectum, cN1–2 (not extranodal), no EMVI] The routine delivery of preoperative RT, either CRT or short-‍course preoperative radiotherapy (SCPRT), to all patients with imaging predicted cN+ remains controversial, particularly because of the low risk of local recurrence associated with good-‍quality TME and removal of the mesorectal nodes en bloc"
},
{
	"page":"ENAS5407_4.3.4.0",
	"text":"Locally advanced rectal cancers (> cT3b, and EMVI+) 4.3.4.0 Locally advanced rectal cancers Neoadjuvant treatment decisions for patients with LARC should be based on preoperative, MRI-predicted CRM (≤ 1 mm), EMVI and more advanced T3 substage (T3c/T3d), which define the risk of both local recurrence and/​‍or synchronous and subsequent metastatic disease MRI also allows risk stratification in terms of the predicted required extent of surgery and the achievement of a clear CRM (> 1 mm) For resectable cancers, where R2 or R1 resection is not indicated by MRI to be likely, standard TME should achieve a curative resection without downstaging/​downsizing The use of preoperative CRT or SCPRT aims to reduce local recurrence and no differences in oncological outcomes between the techniques were reported in two prospective studies in T3/T4 or node-‍positive rectal cancer patients, although adverse events were significantly higher with CRT compared with SCPRT SCPRT with delayed surgery is a useful alternative to conventional short-‍course RT with immediate surgery A local recurrence rate of 5% can be achieved with complete mesorectal excision and a negative CRM"
},
{
	"page":"ENAS5407_4.3.5.0",
	"text":"4.3.5.0 Tumours with threat. resection margin MRI can predict rectal cancers that are unlikely to be amenable to a curative resection without multivisceral resection, either because the tumour abuts or breaches the MRF or there is macroscopic tumour outside the MRF with local extension to pelvic side wall and sacrum or in terms of tumour spread involvement into the lateral compartment To avoid the need for R1 or R2 resection, preoperative treatment is necessary to shrink the cancer back away from the threatened margin i.e. the MRF/‍CRM and CRT significantly increases the chances of R0 resection compared with RT alone"
},
{
	"page":"ENAS5407_4.4.0.0",
	"text":"4.4.0.0 Risk of recurr. accord. to postop. histology Postoperative histopathological features with an impact on the risk of local recurrence, include: pathological TNM stage, T substage, CRM status, the number/​proportion of involved lymph nodes, extracapsular extension, extranodal deposits, tumour differentiation, LVI, EMVI and PNI The risk of local recurrence in patients with histologically involved nodes can be reduced with good quality mesorectal excision, ensuring removal of all mesorectal lymph nodes"
},
{
	"page":"ENAS5407_4.5.0.0",
	"text":"4.5.0.0 Consid. for selection of (C)RT regimen There are two different standards of care for preoperative therapy SCPRT (25 Gy total dose at 5 Gy/​‍fraction during 1 week), followed by immediate surgery (< 10 days from the first radiation fraction); SCPRT with delayed surgery gives similar oncological outcomes to conventional short-‍course RT, with fewer postoperative complications CRT with a recommended dose of 45–50 Gy in 25–28 fractions; a boost with a further 5.4 Gy in 3 fractions can be considered for preoperative RT if the CRM is threatened, and for postoperative RT with 5.4–9.0 Gy in 3–5 fractions according to CRM Either SCPRT or CRT can be used for LARC, unless CRM and/​‍or R0 resection status are predicted by the MDT to be at risk, in which case CRT is recommended Similar R0 resection rates and disease-‍free survival (DFS) are achieved for CRT or SCPRT followed by 5-‍fluorouracil (5-FU)/​‍leucovorin/‍​‍(oxaliplatin) ChT prior to surgery, even with an at-‍risk predicted resection margin (CRM ≤ 1 mm, cT4 or fixed cT3 tumours) Biological molecularly targeted agents have not been successfully integrated into CRT Addition of oxaliplatin to CRT increases pathological complete response (pCR) rates and DFS in selected patients, but also acute toxicity, and the routine addition of oxaliplatin to fluoropyrimidine-‍based CRT is not recommended Intravenous (IV) 5-FU infusion, or oral capecitabine, are recommended in preference to bolus 5-FU during CRT and as adjuvant systemic treatment Preoperative RT or CRT reduces the rate of local recurrence without improvement of overall survival (OS) for mid-‍/​low-‍stage II/​‍III rectal cancers, but is associated with significantly worse intestinal and sexual functions after surgery Preoperative SCPRT or CRT has no benefit in upper rectal cancers (> 12 cm from the anal verge) above the peritoneal reflection, which should be treated as colon cancer Patients with cT4 tumours falling back into the pelvis might benefit from neoadjuvant CRT or neoadjuvant ChT (NACT) alone"
},
{
	"page":"ENAS5407_4.6.0.0",
	"text":"4.6.0.0 Radiotherapy field sizes Detailed recommendations are beyond the scope of these guidelines Expert consensus suggests that widely encompassing nodal regions will be appropriate for patients with advanced tumours, for whom no radical surgery is intended, and smaller volumes for early cancers with the same plan"
},
{
	"page":"ENAS5407_4.7.1.0",
	"text":"4.7.0.0 Preop. (neoadjuvant) chemotherapy 4.7.1.0 Introduction Fluoropyrimidine and oxaliplatin-‍based NACT, either alone or combined with targeted agents, instead of preoperative CRT in cT3 tumours not threatening the CRM and cT4 tumours in the mid- and upper rectum, is associated with pCR in 25% of early-‍stage cases Due to limited outcome data, NACT alone is not recommended for localised, non- metastatic disease outside clinical trials"
},
{
	"page":"ENAS5407_4.7.2.1",
	"text":"4.7.2.0 Assessment after preop. (C)RT 4.7.2.1 Assess. of the primary tumour response The standard methods of clinically re-assessing patients following preoperative therapy are DRE, proctoscopy and MRI re-‍imaging"
},
{
	"page":"ENAS5407_4.7.2.2",
	"text":"4.7.2.2 cCR & a watch-&-wait approach Clinical complete response and a watch-‍and-‍wait approach Following CRT or SCPRT, 10–40% of patients achieve a clinical complete response (cCR) at 12 weeks from the start of treatment, depending on initial stage and currently unknown molecular factors A cCR is the absence of any palpable tumour or irregularity at DRE, no visible lesion at rectoscopy except a flat scar, telangiectasia or whitening of the mucosa and can also include absence of any residual tumour in the primary site and draining lymph nodes on imaging with MRI or ERUS, and negative biopsies from the scar An initially raised CEA level which returns to normal (< 5 ng/mL) after CRT is associated with an increased likelihood of cCR and pCR Dedicated centres have reported encouraging oncological and functional outcome results for selected patients treated with standardised CRT and a non-‍operative strategy Longer follow-‍up and more patients treated in controlled prospective studies are needed to validate the watch-‍and-‍wait approach and large databases, such as the European Registry of Cancer Care (EURECCA) database, will provide more guidance"
},
{
	"page":"ENAS5407_4.7.2.3",
	"text":"4.7.2.3 Patients planned for surgery In LARC, the primary tumour/​CRM should be re-‍evaluated with MRI after CRT prior to resection, although this may both underestimate (poor discrimination between residual tumour and radiation-induced fibrosis) and overestimate pathological response and T downstaging (tumour fragmentation) MRI tumour regression grading (mriTRG) can discriminate/‍​‍determine good and poor responders and predict survival outcomes, but does not correlate well with histopathological tumour regression grade (TRG) The additional value of diffusion-‍weighted imaging, gadofosveset-‍enhanced MRI or Apparent Diffusion Coefficient (ADC) measurements has not been validated CT has relatively low value in assessing local response PET should not be routinely used as a response tool and surgery should not be modified based on the findings Patients with persistent potential CRM involvement on imaging following CRT should be referred to a MDT with experience in multivisceral resection, for tumour removal en bloc The benefit of ChT is unproven and the decision to use it rests with the MDT Distant metastases"
},
{
	"page":"ENAS5407_4.7.2.4",
	"text":"4.7.2.4 Distant Metasteses Routine chest and abdomen restaging after neoadjuvant CRT is not recommended, but patients with more advanced cT4 cancers, threatened CRM and the presence of EMVI, should be re-‍staged within 3 months of original staging to exclude metastatic disease prior to surgery This is not recommended for earlier stage tumours unless clinical progression, including new symptoms or dramatically increased serum CEA, is observed"
},
{
	"page":"ENAS5407_4.7.2.5",
	"text":"4.7.2.5 Pathological assessment of response Several TRGs are in use but the optimal system to define pCR based on TRG remains unclear; at minimum, tumours should be graded as having either pCR, some response or no response Other dynamic histopathological features, i.e. amount of necrosis, regression of EMVI and downstaging of T and N stage, may also define outcomes"
},
{
	"page":"ENAS5407_4.7.2.6",
	"text":"4.7.2.6 Interval to surgery The optimal interval between LARC surgical resection and preoperative CRT or SCPRT remains controversial and requires allowing sufficient time for RT to be effective, but before tumour repopulation, and for the acute reaction to settle to allow safe surgery For SCPRT in resectable cancers not requiring downstaging, immediate surgery (within 7 days from the end of neoadjuvant treatment, and within 0–3 days if the patient is ≥ 75 years [< 10 days from the first radiation fraction]) is recommended Longer intervals between SCPRT or CRT and surgery may enhance pCR rates but risk repopulation, delay the use of postoperative systemic adjuvant ChT and risk subsequent metastases In practice, the timing of surgery varies widely (4–12 weeks) due to patient/​surgeon choice, recovery from treatment and/​‍or waiting list issues"
},
{
	"page":"ENAS5407_4.8.1.0",
	"text":"4.8.0.0 Postoperative therapy 4.8.1.0 Postoperative chemoradiotherapy Preoperative CRT (45-54 Gy, 1.8-2.0 Gy/‍fraction) or SCPRT has better local outcomes than postoperative CRT The use of postoperative CRT (in patients who did not undergo preoperative treatment) to reduce local recurrence can be questioned if a good-‍quality TME can be assured Postoperative CRT may be used selectively in patients with unexpected adverse histopathological features after primary surgery, including positive CRM, perforation in the tumour area and incomplete mesorectal resection, or in other cases with high risk of local recurrence if preoperative RT has not been given, as shown in the table below SUFFICIENT AND NECESSARY INSUFFICIENT AND UNNECESSARY CRM ≤ 1 mm pT1/pT2 pT4b pT3 pN2 extracapsular spread close to MRF CRM > 2 mm Extranodal deposits (N1c) pT4a above peritoneal reflection pN2 if poor mesorectal quality/​defects pN1 If good quality smooth intact mesorectum Sufficient   pN2 low tumours within 4 cm of anal verge (risk of involved LPLN)   Extensive extramural vascular invasion/​perineural invasion close to MRF   Borderline sufficient   pN2 in mid/​‍upper rectum if good mesorectal quality   CRM 1–2 mm   Circumferential obstructing tumours   CRM, circumferential resection margin; CRT, chemoradiotherapy; LPLN, lateral pelvic lymph node; MRF, mesorectal fascia"
},
{
	"page":"ENAS5407_4.8.2.0",
	"text":"4.8.2.0 Postoperative chemotherapy Adjuvant ChT in rectal cancer patients after preoperative CRT/​‍RT with postoperative histology (neoadjuvant pathological [yp]TNM) stage III (and &#39;high-risk&#39; yp stage II) can be considered The level of evidence for benefit is lower than in colon cancer (and limited to DFS) It remains unclear whether the initial clinical or pathological (yp) stage should be used to determine the risk/​‍benefit of adjuvant treatment; downgrading in T or N stage is more of a prognostic marker than a predictive biomarker for adjuvant treatment The decision to use postoperative ChT (fluoropyrimidine alone or combined with oxaliplatin) should take into account the predicted toxicity and the risk of relapse, and should be made jointly by the individual and the clinician"
},
{
	"page":"ENAS5407_5.1.0.0",
	"text":"5.0.0.0 Management of local recurrence 5.1.0.0 Overview Treatment approaches for local recurrence are shown in this figure Surgical salvage is complicated by the loss of the normal anatomical planes and should be carried out by specialist teams If RT has not already been administered, patients should be considered for standard-‍dose preoperative CRT (45-50 Gy in 5-6 weeks) or SCPRT followed by a fluoropyrimidine and oxaliplatin-‍based ChT, prior to attempted resection Re-irradiation to lower doses (with concomitant ChT) is safe in previously irradiated patients and can be used to facilitate a curative resection or to palliate symptoms Systemic palliative ChT to downstage a tumour may be considered where salvage surgery is not an option, although the benefits are unclear Surgical diversion procedures and brachytherapy are recommended palliative options"
},
{
	"page":"ENAS5407_6.1.0.0",
	"text":"6.0.0.0 Management of advanced/​metastatic disease 6.1.0.0 Overview Metastatic rectal cancer management should reflect tumour-‍ and disease-‍related characteristics, patient-‍related factors (comorbidity, socioeconomic factors and expectations of the patient) and treatment-‍related factors, such as toxicity ChT alone may be insufficient where the primary tumour remains in situ and untreated, and local RT palliation of rectal symptoms may be required SCPRT is preferable to CRT, allowing systemic ChT to start within 2 weeks from treatment initiation, palliating symptoms in most patients and avoiding salvage stoma for some If the patient has a chance for cure (oligometastatic disease), rapid local control with effective systemic ChT and appropriate sequence/‍​timing of metastasectomy is the aim SCPRT with triplet ChT (capecitabine/‍​oxaliplatin/​bevacizumab) facilitates resection of borderline resectable liver metastasis and the primary tumour, but in the absence of randomised studies, the MDT should be responsible for critical treatment decisions in patients with potentially curable metastatic disease"
},
{
	"page":"ENAS5407_7.0.0.0",
	"text":"7.0.0.0 Personalised medicine There are no molecular markers identified in rectal cancers to guide treatment approaches or to predict response to RT or CRT Rectal cancers with distant metastases should be studied for RAS and BRAF mutational status and the other requirements addressed in the European Society for Medical Oncology (ESMO) consensus guidelines on metastatic colorectal cancer"
},
{
	"page":"ENAS5407_8.1.0.0",
	"text":"8.0.0.0 Follow-‍up, long-‍term implications and survivorship 8.1.0.0 Overview Follow-‍up/​surveillance with clinical examination, imaging and colonoscopy can be conducted as shown in this figure Clinical examination and pelvic imaging using MRI and/​‍or CT are recommended, with CT of the chest, abdomen and pelvis for distant metastases Routine use of PET-‍CT as surveillance is not recommended, although it may be helpful for defining other unrecognised sites of disease when recurrence is diagnosed CEA screening with CT monitoring increases the rate of surgical resection of recurrence with curative intent but this approach is only recommended up to 5 years following surgery Long-‍term side effects of treatment, including lower genitourinary toxicities (e.g. erectile dysfunction, dyspareunia and urinary incontinence) should be monitored Surveillance should address social, financial and emotional aspects together with practical and functional consequences to maximise survivors’ long-‍term well-‍being Evidence supports late effects/​survivorship clinics for patients who have received pelvic RT A minimum provisional surveillance recommendation for average-‍risk patients is as follows: Clinical assessment every 6 months for 2 years A completion colonoscopy within the first year, if not done at the time of diagnostic work-‍up History and colonoscopy with resection of colonic polyps every 5 years, up to the age of 75 years A minimum of two CTs of the chest, abdomen and pelvis in the first 3 years and regular serum CEA tests (at least every 6 months in the first 3 years) High-‍risk patients (CRM+) may merit more proactive surveillance for local recurrence"
},
{
	"page":"ENAS5407_9.1.0.0",
	"text":"9.0.0.0 Summary of recommendations 9.1.0.0 Diagnosis & pathology Diagnosis is based on a DRE and endoscopy, with biopsy for histopathological confirmation Rectal cancers have distal extension to ≤ 15 cm from the anal margin, using rigid sigmoidoscopy, and are categorised as low (up to 5 cm), middle (from > 5 to 10 cm) or high (from > 10 up to 15 cm) There is a wide overlap of molecular genomic profiles of left-‍sided /​ sigmoid with rectal cancer; so rectal cancer cannot be seen as a molecularly defined different entity"
},
{
	"page":"ENAS5407_9.2.1.0",
	"text":"9.2.0.0 Staging and risk assessment 9.2.1.0 Overview Management should be by an MDT of radiologists, surgeons, radiation oncologists, medical oncologists and pathologists A history and physical examination, including DRE, full blood count, liver and renal function tests, serum CEA and CT scan of thorax and abdomen, should be carried out to define functional status and presence of metastases PET-‍CT may provide information on extra-‍pelvic disease Pretreatment geriatric assessment is recommended in patients over 70 years Rigid rectoscopy and preoperative colonoscopy to the caecal pole or virtual colonoscopy are required to exclude synchronous colonic tumours, and, if unavailable, completion colonoscopy is recommended within 6 months of surgery Pelvic MRI should be carried out to select patients for preoperative management and to define the extent of surgery In staging disease, further subclassification of cT3 is recommended, clinical nodal staging is unreliable, even using ERUS, CT and MRI combined, and the relationship between tumour and MRF is more important than lymph node status PET-‍CT should not be used routinely for initial staging, but can be used in conjunction with MRI and CT to evaluate the risk of metastases Bone scan and brain imaging should only be carried out if warranted by symptoms"
},
{
	"page":"ENAS5407_9.2.2.0",
	"text":"9.2.2.0 Histopathology T1 tumours can be classified according to Haggitt&#039;s sub-‍classification if the cancer is pedunculated and according to Kudo/​‍Kikuchi (sm)-‍system if in a sessile adenoma Resection en bloc is recommended for accurate assessment of invasion in the resection margin and the deepest area According to Japanese guidelines, radical surgery and removal of lymph nodes is recommended for high-‍risk pathological features Involved CRM rate (i.e. < 1 mm) and TME quality are surrogates for good oncological outcomes At least 12 regional lymph nodes should be examined and their margins documented For mesorectal resections, histopathological examination should include a photographic record of the surgical specimen and assessment of TME quality ENE of nodal metastases, EMVI, PNI and tumour budding should be evaluated"
},
{
	"page":"ENAS5407_9.3.1.1",
	"text":"Very early cT1N0, with low grade (G1/G2) 9.3.0.0 Management of local/‍​‍locoregional disease 9.3.1.0 Risk-‍adapted treatment 9.3.1.1 Very early cT1No, with low grade (G1/​G2) Local excisional procedures are appropriate as single modalities for early cancers (cT1N0 without adverse features like G3, V1, L1) TME is the standard salvage option for unfavourable pTNM following local excision Local RT may be used as an alternative to local surgery, alone or combined CRT"
},
{
	"page":"ENAS5407_9.3.1.2",
	"text":"Early rectal cancer not suitable for local excision (cT1–cT2; cT3a/b if middle or high, N0 [or also cN1 if high], MRF clear, no EMVI) 9.3.1.2 Rectal CA not suitable for local excision Radical TME is recommended for more advanced tumours (up to and including cT2c/​T3a/​b) and the standard of care for surgery includes excision of all mesorectal fat, including all lymph nodes A partial mesorectal excision with a distal mesorectal margin of at least 5 cm can be considered in upper rectal cancer Local excisional TEM can be considered for cT1 tumours or in elderly or fragile patients TaTME may facilitate pelvic and distal mesorectal dissection in low rectal tumours MRI is recommended to select patients suitable for abdominoperineal excision For cT2 tumours < 4 cm, local excision after preoperative RT/​‍CRT is not routinely recommended outside clinical trials, except for elderly, fragile patients at high surgical risk TME alone can be considered for early, favourable cases not suitable for local excision (i.e. cT1-2 but with adverse pathological features and some cT3a/​b without MRI-‍identified involvement of MRF) when located above the levators"
},
{
	"page":"ENAS5407_9.3.1.3",
	"text":"9.3.1.3 Intermediate/‍​more locally advan. rectal CA Intermediate/more locally advanced rectal cancers (cT3a/b [very low, levators clear, MRF clear] or cT3a/b in mid- or high rectum, cN1–2 (not extranodal), no EMVI] The routine delivery of preoperative RT, either CRT or SCPRT, to all patients with imaging predicted cN+ is not recommended"
},
{
	"page":"ENAS5407_9.3.1.4",
	"text":"Locally advanced rectal cancers (> cT3b, and EMVI+) 9.3.1.4 Locally advanced rectal cancers Neoadjuvant treatment decisions for patients with LARC should be based on preoperative, MRI-predicted CRM (≤ 1 mm), EMVI and more advanced T3 substage (T3c/​T3d) For resectable cancers, where R2 or R1 resection is not indicated by MRI to be likely, standard TME should achieve a curative resection without downstaging/​ downsizing Preoperative CRT or SCPRT give similar oncological outcomes but adverse effects occur more frequently with CRT SCPRT with delayed surgery is a useful alternative to conventional short-‍course RT with immediate surgery"
},
{
	"page":"ENAS5407_9.3.1.5",
	"text":"9.3.1.5 Tumours with threat. resection margin MRI can predict rectal cancers unlikely to be amenable to a curative resection without multivisceral resection and for which preoperative treatment with CRT increases the chances of R0 resection, either because the tumour abuts or breaches the MRF or there is macroscopic tumour outside the MRF with local extension to pelvic side wall and sacrum or in terms of tumour spread involvement into the lateral compartment To avoid the need for R1 or R2 resection, preoperative treatment is necessary to shrink the cancer back away from the threatened margin i.e. the MRF/CRM and CRT significantly increases the chances of R0 resection compared with RT alone"
},
{
	"page":"ENAS5407_9.3.2.0",
	"text":"9.3.2.0 Risk of recurr. accord. to postop. histology Postoperative histopathological features with an impact on the risk of local recurrence, include: pathological TNM stage, T substage, CRM status, the number/​proportion of involved lymph nodes, extracapsular extension, extranodal deposits, tumour differentiation, LVI, EMVI and PNI The risk of local recurrence in patients with histologically involved nodes can be reduced with good quality mesorectal excision, ensuring removal of all mesorectal lymph nodes"
},
{
	"page":"ENAS5407_9.3.3.0",
	"text":"9.3.3.0 Consid. for selection of (C)RT regimen The standards of care for preoperative treatment are SCPRT (25 Gy total dose at 5 Gy/​‍fraction during 1 week), followed by immediate surgery (< 10 days from the first radiation fraction) and CRT with a recommended dose of 45-50 Gy in 25-28 fractions; a boost with a further 5.4 Gy in 3 fractions can be considered for preoperative RT if the CRM is threatened, and for postoperative RT routinely with 5.4-9.0 Gy in 3-5 fractions according to CRM CRT is recommended where CRM and/​‍or R0 resection status are predicted by the MDT to be at risk Routine addition of oxaliplatin to fluoropyrimidine-‍based CRT is not recommended 5-FU IV infusion, or oral capecitabine, are recommended in preference to bolus 5-FU during CRT and as adjuvant systemic treatment Preoperative RT or CRT reduces the rate of local recurrence for mid/​‍low stage II/​‍III rectal cancers, but is associated with significantly worse postoperative intestinal and sexual functions Upper rectal cancers (> 12 cm from the anal verge) above the peritoneal reflection should be treated as colon cancer Patients with cT4 tumours falling back into the pelvis might benefit from neoadjuvant CRT or NACT alone"
},
{
	"page":"ENAS5407_9.3.4.0",
	"text":"9.3.4.0 Radiotherapy field sizes Detailed recommendations are beyond the scope of these guidelines"
},
{
	"page":"ENAS5407_9.3.5.1",
	"text":"9.3.5.0 Preoperative (neoadjuvant) chemotherapy 9.3.5.1 Overview Fluoropyrimidine and oxaliplatin-‍based NACT, either alone or combined with targeted agents, can be used for cT3 tumours not threatening the CRM and cT4 tumours in the mid and upper rectum NACT alone is not recommended for localised, non-‍metastatic disease outside clinical trials"
},
{
	"page":"ENAS5407_9.3.5.2",
	"text":"9.3.5.2 Assessment after preop. (C)RT Assessment of the primary tumour response The standard methods of clinical reassessment are clinical examination using DRE, proctoscopy and MRI re-‍imaging Clinical complete response and a watch-‍and-‍wait approach An initially raised CEA level which returns to normal (< 5 ng/​mL) after CRT is associated with an increased likelihood of cCR and pCR Further validation of a watch-‍and-‍wait approach is required Patients planned for surgery In LARC, the primary tumour/​CRM should be re-‍evaluated with MRI after CRT prior to resection mriTRG can predict survival outcomes but does not correlate well with histopathological TRG CT has relatively low value in assessing local response PET should not be routinely used as a response tool and surgery should not be modified based on the findings Patients with persistent potential CRM involvement on imaging following CRT should be referred to a MDT for tumour removal en bloc Distant metastases Routine restaging of chest and abdomen after neoadjuvant CRT is not recommended, but patients with cT4 cancers, threatened CRM and EMVI should be re-‍staged within 3 months of original staging This is only applicable for earlier stage tumours when clinical progression is observed Pathological assessment of response As a minimum, tumours should be graded as having either pCR, some response or no response Other dynamic histopathological features, i.e. amount of necrosis, regression of EMVI and downstaging of T and N stage, may also help to define outcomes Interval to surgery For SCPRT in resectable cancers not requiring downstaging, immediate surgery (within 7 days from the end of neoadjuvant treatment, and within 0-3 days if the patient is ≥ 75 years [< 10 days from the first radiation fraction]) is recommended"
},
{
	"page":"ENAS5407_9.3.6.0",
	"text":"9.3.6.0 Postoperative therapy Postoperative chemoradiotherapy Postoperative CRT may be used selectively in patients with unexpected adverse histopathological features after primary surgery, including positive CRM, perforation in the tumour area and incomplete mesorectal resection, or in other cases with high risk of local recurrence if preoperative RT has not been given Postoperative chemotherapy Adjuvant ChT in rectal cancer patients after preoperative CRT/​‍RT with postoperative histology (ypTNM) stage III (and &#39;high-‍risk&#39; yp stage II) can be considered, although the level of evidence is lower than in colon cancer The decision to use postoperative ChT (fluoropyrimidine alone or combined with oxaliplatin) should take into account the predicted toxicity and the risk of relapse"
},
{
	"page":"ENAS5407_9.4.0.0",
	"text":"9.4.0.0 Management of local recurrence Surgical salvage should be carried out by specialist teams If RT has not already been administered, patients should be considered for standard dose preoperative CRT (45-50 Gy in 5-6 weeks), or SCPRT followed by a fluoropyrimidine and oxaliplatin-‍based ChT, prior to attempted resection In patients previously irradiated, re-irradiation to lower doses (with concomitant ChT) is safe and can be used to facilitate a curative resection or to palliate symptoms Systemic palliative ChT to downstage a tumour and enable salvage surgery may be considered Palliative surgical diversion procedures and brachytherapy are effective palliative options"
},
{
	"page":"ENAS5407_9.5.0.0",
	"text":"9.5.0.0 Mgmt. of advanced/​ met. disease Metastatic rectal cancer management should reflect tumour-‍, disease-‍, patient-‍ and treatment-‍related factors ChT alone may be insufficient where the primary tumour remains in situ and untreated and local RT palliation of rectal symptoms may be required SCPRT is preferable to CRT Rapid local control with effective systemic ChT and appropriate sequence/‍​timing of metastasectomy is the aim of treatment where cure is a possibility SPCRT with capecitabine/‍​oxaliplatin/​bevacizumab can be used to facilitate resection borderline resectable liver metastases and primary tumour The MDT should be responsible for critical treatment decisions in patients with potentially curable metastatic disease"
},
{
	"page":"ENAS5407_9.6.0.0",
	"text":"9.6.0.0 Personalised medicine There are no molecular markers to guide treatment approaches or to predict response to RT or CRT Rectal cancers with distant metastases should be studied for RAS and BRAF mutational status and the other requirements addressed in the ESMO consensus guidelines on metastatic colorectal cancer"
},
{
	"page":"ENAS5407_9.7.0.0",
	"text":"9.7.0.0 Follow-‍up, long-‍term implications and survivorship Clinical examination and pelvic imaging using MRI and/​‍or CT are recommended, with CT of the chest, abdomen and pelvis for distant metastases Routine use of PET-‍CT as surveillance is not recommended Long-‍term side effects of treatment should be monitored A minimum provisional surveillance recommendation for average-‍risk patients includes: clinical assessment every 6 months for 2 years; a completion colonoscopy within the first year, if not done at work-‍up; a history and colonoscopy, with resection of colonic polyps every 5 years, up to the age of 75 years; and a minimum of two CTs of the chest, abdomen and pelvis in the first 3 years and regular serum CEA tests High-‍risk patients (CRM+) may require more proactive surveillance"
},
{
	"page":"ENAS5407_10.0.0.0",
	"text":"10.0.0.0 Glossary 5-FU 5-‍fluorouracil ACD anal cancer death ADC Apparent Diffusion Coefficient AFAP attenuated familial adenomatous polyposis AJCC American Joint Committee for Cancer APE abdomino-‍‍perineal excision APPA anterior posterior/‍‍posterior anterior BSC best supportive care CA19-9 carbohydrate antigen 19-9 CAPOX capecitabine/‍oxaliplatin cCR clinical complete remission CEA carcinoembryonic antigen CEUS contrast-‍‍enhanced ultrasound cfDNA cell-‍free DNA ChT chemotherapy CIN cervical intra-epithelial neoplasia CLM colorectal liver metastases cN clinical node stage CPGs Clinical Practice Guidelines CRC colorectal cancer CRM circumferential resection margin CRT chemoradiotherapy cT clinical tumour stage CT computed tomography CTC circulating tumour cell ctDNA circulating tumour DNA DCC deleted in colon cancer DFS disease-‍‍free survival dMMR mismatch repair deficient DNA deoxyribonucleic acid DPD dihydropyrimidine dehydrogenase DRE digital rectal examination EAUS endo-‍anal ultrasound EGFR epidermal growth factor receptor EMVI extramural vascular invasion ENE extranodal extension ERCC1 excision repair cross-‍‍complementation group1 ERUS endoscopic rectal ultrasound ESMO European Society for Medical Oncology ESSO European Society of Surgical Oncology ESTRO European Society for Radiotherapy and Oncology EU European Union EUA examination under anaesthesia EURECCA European Registry of Cancer Care FA folinic acid FAP familial adenomatous polyposis FDG fluorodeoxyglucose FDG-‍PET fluorodeoxyglucose positron emission tomography FIT faecal immunochemical test FLOX 5-‍fluorouracil/leucovorin (folinic acid)/‍oxaliplatin FOBT faecal occult blood test FOLFIRI leucovorin/infusional 5-FU/irinotecan FOLFOX leucovorin/infusional 5-FU/oxaliplatin FOLFOXIRI leucovorin/infusional 5-FU/oxaliplatin/irinotecan FP fluoropyrimidine FS flexible sigmoidoscopy G Grade gFOBT guaiac faecal occult blood test GI gastrointestinal H&E hematoxilin and eosin HAART highly active antiretroviral therapy HDR high dose-‍rate HER2 human epidermal growth factor receptor 2 HIPEC hyperthermic intraperitoneal chemotherapy HIV human immunodeficiency virus HPV human papillomavirus IHC immunohistochemistry IMRT intensity-‍modulated radiotherapy IPAA ileal pouch-‍‍anal anastomosis IRA ileorectal anastomosis IV intravenous L lymphatic invasion LARC locally advanced rectal cancer LAT local ablative treatment LND laternal node dissection LPLN lateral pelvic lymph node LRF locoregional failure rate LV leucovorin MAC modified Astler-‍‍Coller classification MAP MUTYH-‍‍associated polyposis mCRC metastatic colorectal cancer MDT multidisciplinary team MMC mitomycin C MMR mismatch repair MRF mesorectal fascia MRI magnetic resonance imaging mriTRG MRI tumour regression grading MSI microsatellite instability MSI-H microsatellite instability high mt mutant NACT neoadjuvant chemotherapy NCCN National Comprehensive Cancer Network NED no evidence of disease OMD oligometastatic disease OS overall survival pCR pathological complete response PET positron emission tomography PET-CT positron emission tomography-computed tomography PNI perineural invasion PS performance status PTEN phosphatase and tensin homologue QoL quality of life R0 resection with negative margins R1 resection with microscopic residual disease RCT randomised controlled trial RFA radiofrequency ablation RR response rate RT radiotherapy RTOG Radiation Therapy Oncology Group SBRT stereotactic body radiotherapy SCCA squamous cell carcinoma of the anus SCCAg squamous cell carcinoma antigen SCPRT short-course preoperative radiotherapy SIRT selective internal radiotherapy sm submucosa TACE transarterial chemoembolisation TaTME transanal total mesorectal excision TEM transanal endoscopic microsurgery TGF-α transforming growth factor-‍‍α TGFBR2 transforming growth factor-‍‍beta receptor II Tis carcinoma in situ TME total mesorectal excision TNM tumour node metastasis TRG tumour regression grade TS thymidylate synthase TSER thymidylate synthase enhancer region UGT1A1 uridine diphosphate glucuronosyltransferase 1A1 UICC Union for International Cancer Control US ultrasound V vascular invasion VEGF vascular endothelial growth factor VIN vulval intra-‍‍epithelial neoplasia wt wild-‍type XELOX capecitabine/‍oxaliplatin yp neoadjuvant pathological staging"
}
]